Pilot human trial for image-guided cancer surgery tool

The Spectropen, a hand-held device developed by Emory and Georgia Tech scientists, was designed to help surgeons see the margins of tumors during surgery.

Some of the first results from procedures undertaken with the aid of the Spectropen in human cancer patients were recently published by the journal PLOS One. A related paper discussing image-guided removal of pulmonary nodules was just published in Annals of Thoracic Surgery.

To test the Spectropen, biomedical engineer Shuming Nie and his colleagues have been collaborating with thoracic surgeon Sunil Singhal at the University of Pennsylvania.

As described in the PLOS One paper, five patients with cancer in their lungs or chest participated in a pilot study at Penn. They received an injection of the fluorescent dye indocyanine green (ICG) before surgery.

ICG is already FDA-approved for in vivo diagnostics and now used to assess cardiac and liver function. ICG accumulates in tumors more than normal tissue because tumors have leaky blood vessels and membranes. The Spectropen shines light close to the infrared range on the tumor, causing it to glow because of the fluorescent dye.

[This technique resembles the 5-aminolevulinic acid imaging technique for brain tumor surgery being tested by Costas Hadjipanayis, described in Emory Medicine.]

In one case from the PLOS One article, the imaging procedure had some tangible benefits, allowing the surgeons to detect the spread of cancerous cells when other modes of imaging did not. According to a Penn news release:

In four of the patients, the surgeon could easily tell tumor from non-tumor by sight and by feel. In a fifth patient, however, though a CT and PET scan indicated that the tumor was a solitary mass, NIR imaging revealed glowing areas in what were thought to be healthy parts of the lung.

“It turns out he had diffuse microscopic cancer in multiple areas of the lung,” says Penn surgeon David Holt. “We might have otherwise called this Stage I, local disease, and the cancer would have progressed. But because of the imaging and subsequent biospy, he underwent chemotherapy and survived.”

At Emory, surgeons David Kooby and James Provenzale have been testing the Spectropen in a clinical trial led by Provenzale. Kooby is director of surgical oncology at Emory-Saint Joseph’s.PancTumorMargin

Nie reports that during a recent surgery for pancreatic cancer, his colleague Jian Xu, Kooby and Provenzale made a similar detection of additional tumor tissue beyond the surgeons’ initial estimate. This guided the surgeons to perform a second resection, making tumor removal more complete. Diagram at right; photo available upon request.

One limitation of the technique, which is described in the PLOS One paper, is that ICG also absorbs into inflamed tissue. In some patients that had inflammation around their tumors, it was difficult to distinguish cancer from inflamed tissue.

“That was to be expected,” Nie says. “Inflammation is often part of a tumor. To achieve the necessary level of discrimination, we know that we need to have an imaging agent that is targeted molecularly to cancer cells.”

Nie says that is a potential solution would be to use a fluorescent dye conjugated to a small peptide or other chemical, such as folic acid, which more specifically binds cancer cells. Conjugating larger proteins, such as antibodies, to the dye makes it diffuse too slowly for imaging applications.

“It has to get there fast and clear out fast,” he says.

The Spectropen is being developed as a commercial product by the Atlanta-based spinoff company Spectropath.





Posted on by Quinn Eastman in Cancer Leave a comment

About the author

Quinn Eastman

Science Writer, Research Communications qeastma@emory.edu 404-727-7829 Office

Add a Comment